Elacestrant(Orserdu) is a novel estrogen receptor antagonist for patients with specific types of breast cancer. This article will systematically explain the key information of the drug from three aspects: medication guidelines, precautions and indications, so as to help patients and medical practitioners better understand its clinical application and management points.
Guidelines for the use of Elacestrant
Elacestrant was developed by Stemline in the United States and approved by the FDA for marketing in 2023. The drug targets ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations by inhibiting estrogen receptor activity. The following analyzes its usage specifications from two aspects: basic information and usage and dosage.
Basic information about the drug
Elacestrant is available as a tablet with 345 mg and 86 mg. The original drug is produced by Stemline in the United States; Lucius Laos offers generic drugs at significantly lower prices. Distinguishable tablet properties: 345mg is an oval light blue tablet marked "MH"; 86 mg is a round tablet of the same color, labeled "ME". Storage needs to be sealed in the dark, and the temperature should be controlled at 15°C-30°C.
Standardize the medication regimen
The recommended dose is 345 mg daily with a meal and swallowed whole to reduce gastrointestinal reactions. If you miss a dose for more than 6 hours, you need to skip the dose, and you do not need to make up the dose after vomiting. Patients with moderate to severe liver impairment need to adjust the dose: Child-Pugh grade B is reduced to 258 mg, and grade C is contraindicated. Combination with CYP3A4 inducers/inhibitors may affect efficacy and should be strictly avoided.
It is recommended to formulate a treatment plan under the guidance of a professional physician and regularly monitor drug reactions.
Precautions for the administration of Elacestrant
The clinical use of Elacestrant needs to balance efficacy and safety. The following is to clarify the key points of risk prevention and control in the treatment process from the aspects of adverse reaction management and drug use in special populations.
Prevention and control of adverse reactions
More than 10% of patients have musculoskeletal pain, nausea, and dyslipidemia, with grade 3 to 4 hypercholesterolemia occurring in 0.9% to 2.2%. Baseline blood lipid data should be established before medication, and monitored every 3 months during treatment. If severe vomiting or abnormal liver function occurs, the dose should be adjusted or the dose should be suspended.
Special population management
Pregnant women may cause fetal malformations, and strict contraception is required until 1 week after discontinuation. Breastfeeding women should stop breastfeeding. Safety data are lacking in children and older patients over 75 years of age and require careful evaluation. Patients with hepatic impairment need to adjust the dose according to the Child-Pugh grade, and patients with renal insufficiency do not need special adjustments.
Through dynamic monitoring and precise management, the treatment risk can be minimized while ensuring the efficacy, and safe medication support can be provided for different groups of patients.
Indications for patients with Elacestrant
The drug has a clear therapeutic value for specific breast cancer subtypes. The following analyzes its clinical positioning from the aspects of applicable population and treatment mechanism.
Precision treatment of groups
It is suitable for postmenopausal women or adult men with ER/HER2- advanced breast cancer and ESR1 mutation confirmed by genetic testing. In these patients, after failure of at least one endocrine therapy, Elacestrant significantly prolongs progression-free survival and is the preferred second-line treatment.
Mechanism of action analysis
The drug is a selective estrogen receptor degrader (SERD), and alastrone blocks the estrogen signaling pathway and induces receptor degradation by competitively binding to the ERα receptor. Compared with fulvestrant, its oral administration method significantly improves the convenience of medication and has a stronger inhibitory effect on ESR1 mutant strains.
Clarifying the scope of indications and mechanism of action will help screen the beneficiary population and provide more precise treatment options for patients with advanced breast cancer.
